Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T5354 |
IRAK4-IN-7
CA-4948 |
IRAK | Immunology/Inflammation; NF-κB |
IRAK4-IN-7 (CA-4948) 是白介素 1 受体相关激酶 4 (IRAK4) 的选择性抑制剂,口服有活性。它可用于研究癌症以及炎症疾病。 | |||
T9924 |
Obinutuzumab
奥滨尤妥珠单抗,Obinutuzumab/afutuzumab |
Others | Others |
Obinutuzumab (Obinutuzumab/afutuzumab)/afutuzumab 是一种新型糖工程化 II 型 CD20单克隆抗体,用于研究非霍奇金淋巴瘤。 | |||
T8380 |
Bendamustine
SDX105,宾达氮芥 |
Apoptosis; Others; DNA Alkylator/Crosslinker | Apoptosis; DNA Damage/DNA Repair; Others |
Bendamustine (SDX105) 是一种嘌呤类似物,是一种 DNA 交联剂,具有烷基化、抗癌和抗代谢作用。它可激活 DNA 损伤反应和细胞凋亡。 | |||
T35617 |
Mitoguazone
MGBG,Methyl-GAG |
Apoptosis; HIV Protease | Apoptosis; Microbiology/Virology; Proteases/Proteasome |
Mitoguazone (Methyl-GAG) 是一种可透过血脑屏障的选择性的 S-腺苷-蛋氨酸脱羧酶 (S-adenosyl-methionine decarboxylase) 抑制剂,可破坏多胺的生物合成。Mitoguazone 是一种具有抗肿瘤活性的合成多羰基衍生物,可抑制 HIV DNA 整合到单核细胞和巨噬细胞中的细胞 DNA 中,诱导细胞凋亡 (apoptosis)。Mitoguazone 具可用于预防急性白血病,霍奇金淋巴瘤和非霍奇金淋巴瘤。 | |||
T76692 |
Mosunetuzumab
BTCT-4465A |
Others | Others |
Mosunetuzumab (BTCT-4465A) 是一种基于免疫球蛋白 G1 且靶向 CD20 (B 细胞) 和 CD3 (T 细胞) 的人源化抗体。Mosunetuzumab 重定向 T 细胞以接合和消除恶性 B 细胞,可用于研究复发或难治性 (R/R) B 细胞非霍奇金淋巴瘤 (B-NHL)和难治性滤泡性淋巴瘤。 | |||
T78686 |
Apoptosis inducer 11
|
Apoptosis | Apoptosis |
Apoptosisinducer 11(compound 3u)通过线粒体途径引发细胞凋亡。在非霍奇金淋巴瘤细胞系中,该化合物导致G2/M期停滞和S期显著减少。 | |||
T40901 |
Aderbasib
INCB007839,INCB7839 |
||
Aderbasib (INCB007839) is a highly potent and orally active hydroxamate-based inhibitor of ADAM10 and ADAM17, with low nanomolar affinity. This compound demonstrates strong antineoplastic activity and holds potential for cancer research in various areas, such as diffuse large B-cell non-Hodgkin lymphoma, HER2-positive breast cancer, gliomas, and more. | |||
T78331 |
Epcoritamab
GEN3013 |
||
Epcoritamab (GEN3013) 是一种双特异性IgG1抗体,它能够将 CD3的T细胞引导至CD20阳性的肿瘤细胞,实现T细胞与肿瘤细胞的靶向联系。 | |||
T76768 | Pinatuzumab | ||
Pinatuzumab为针对CD22细胞表面抗原的单克隆抗体。作为合成抗体活性分子偶联物(ADC)成分,适用于非霍奇金淋巴瘤(NHL)等多种疾病的研究。 | |||
T76765 | Veltuzumab | ||
Veltuzumab (IMMU-106) 为一种针对CD20的人源化单克隆抗体。其在Daudi细胞系中显示出较低的EC50值,范围为0.08-0.09 μg/mL。Veltuzumab适用于非霍奇金淋巴瘤(NHL)等癌症的研究。 | |||
T82078 |
Iladatuzumab
MCDS0593A |
||
Iladatuzumab (MCDS0593A) 为人源化IgG1抗CD79B单克隆抗体。该抗体作为ADC活性分子Iladatuzumab vedotin (DCDS0780A) 的构建模块,Iladatuzumab vedotin 展现出治疗B细胞非霍奇金淋巴瘤 (B-NHL) 的研究潜力。 | |||
T68485 | Apilimod HCl | ||
Apilimod dimesylate is a potent and selective PIKfyve inhibitor. It exhibits no significant activity at other lipid kinases and protein kinases, including PIP4K, PIP5K, mTOR, PI3K and PI4K. Apilimod dimesylate inhibits cellular entry by SARS-CoV-2, MERS-CoV and MHV S pseudovirions. It reduces the number of SARS-CoV-2-infected hiPSC-derived pneumocyte-like cells by 85% and inhibits SARS-CoV-2 replication in donor lung tissue. It also exhibits selective cytotoxicity in B-cell non-Hodgkin lymphoma ... | |||
T73700 |
Daunorubicin citrate
|
||
Daunorubicin citrate(Daunomycin citrate)作为一种拓扑异构酶 II(topoisomerase II)抑制剂,展现出有效的抗肿瘤活性,通过抑制 DNA 和 RNA 合成(DNA and RNA synthesis)发挥作用。作为一种细胞毒性药物,Daunorubicin citrate 能够抑制癌细胞活性,并诱导细胞凋亡(apoptosis)和坏死(necrosis),属于蒽环类抗生素范畴。该化合物广泛应用于包括白血病、非霍奇金淋巴瘤、尤文氏肉瘤、维尔姆斯氏瘤在内的多种癌症和感染研究领域。 |